Skip to Content
Merck
  • Binding of 1-benzopyran-4-one derivatives to aldose reductase: a free energy perturbation study.

Binding of 1-benzopyran-4-one derivatives to aldose reductase: a free energy perturbation study.

Bioorganic & medicinal chemistry (2002-03-12)
Giulio Rastelli, Luca Costantino, M Cristina Gamberini, Antonella Del Corso, Umberto Mura, J Mark Petrash, Anna Maria Ferrari, Sara Pacchioni
ABSTRACT

The relative binding affinities to human aldose reductase (ALR2) of three new 7-hydroxy-2-benzyl-4H-1-benzopyran-4-one inhibitors were predicted by free energy perturbation (FEP) simulations. Molecular substitutions were specifically designed to investigate the role of hydrogen bonding at the active site of ALR2. Starting from the lead inhibitor 7-hydroxy-2-(4'-hydroxybenzyl)-4H-1-benzopyran-4-one, the 4'-hydroxyl was mutated to methyl and to trifluoromethyl, and an hydroxyl at position 8 was additionally introduced. Once synthesized and tested as inhibitors of ALR2, the compounds displayed variations of K(i) that were in qualitative to quantitative agreement with the calculated relative free energies of binding. The results, discussed in terms of balance between free energies of solvation and free energies of binding to ALR2, elucidate the importance of hydrogen bonding with Thr113 and with Trp111 and cofactor, and provide a rationale to the observed differences in binding affinities.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Methyl 4-methoxyphenylacetate, 97%